loader from loading.io

The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

Release Date: 05/22/2024

Exploring Psychedelic Benefits for Chronic Illness with Christina P. Kantzavelos, LCSW, MSW, MLIS show art Exploring Psychedelic Benefits for Chronic Illness with Christina P. Kantzavelos, LCSW, MSW, MLIS

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Christina P. Kantzavelos, LCSW, MSW, MLIS joins to discuss the use of psychedelics to address chronic illness. Christina is an international psychotherapist, coach, writer and artist, who specializes in treating clients with chronic illness, and complex trauma utilizing various modalities, including psychedelic assisted therapy. In this conversation, Christina overviews the complex mental and physical health impacts of chronic pain conditions and shares her expertise on psychedelic and non-psychedelic treatments for these conditions. Christina mentions that chronic pain can...

info_outline
The Dangers of The Dangers of "Ayahuasca Told Me…" with Jerónimo Mazarrasa

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Jerónimo Mazarrasa joins to discuss how to interpret visions and insights disclosed during ayahuasca journeys more effectively. Jerónimo is Program Director at ICEERS, founder of ICEERS Academy, and creator of AyaSafety, an online course for people interested in increasing the safety of ayahuasca ceremonies. To start, Jerónimo emphasizes that answering the question of whether ayahuasca visions originate in the plant medicine itself or if these are just disclosures of one’s own subconscious is actually not what's most important. Instead, he suggests that in either case,...

info_outline
Can Psychedelics Lead to False Beliefs? with Hugh McGovern, PhD show art Can Psychedelics Lead to False Beliefs? with Hugh McGovern, PhD

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Hugh McGovern, PhD joins to discuss his research on the impact of psychedelics on beliefs. Dr. McGovern is a Research Fellow at the School of Medicine, Deakin University, Melbourne, Australia. To start, Dr. McGovern introduces the inference or predictive processing framework utilized in his paper . He explains the role of prediction in cognition, showing how insights occur when our existing perspectives are unable to make sense of our experience. In this vein, Dr. McGovern discusses how the psychedelic experience disrupts our normal modes of prediction and perception,...

info_outline
Psychedelics for Grief and Loss with Heather A. Lee, LCSW show art Psychedelics for Grief and Loss with Heather A. Lee, LCSW

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Heather A. Lee, LCSW joins to discuss the topic of psychedelic healing for grief and loss. Heather is a licensed psychotherapist, educator, speaker, and consultant. With over 30 years of practice in mental health, her focus is on supporting midlife and beyond women as they navigate life transitions. In this conversation, Heather explores the ways psychedelic healing may have transformative contributions to peoples’ journeys navigating grief and loss. She explains that we live in a culture that doesn’t have a good understanding of grief, how to navigate it, or how to...

info_outline
Ketamine-Assisted Psychotherapy for Anxiety with Thomas Kim, MD show art Ketamine-Assisted Psychotherapy for Anxiety with Thomas Kim, MD

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Thomas Kim, MD joins to discuss ketamine-assisted psychotherapy for anxiety. Dr. Kim is the Chief Medical Officer of Noma Therapy, which is a ketamine-assisted psychotherapy program available via telehealth and in-person with licensed therapists. He has devoted 20 years of his professional life to realizing a value-based approach to healthcare through telehealth. In this conversation, Dr. Kim shares his journey of working in early telehealth contexts to now working with ketamine. He discusses the research on ketamine treatments for anxiety and explains the significant...

info_outline
Guruism and Cult Dynamics in Psychedelic Practices with Joseph Holcomb Adams show art Guruism and Cult Dynamics in Psychedelic Practices with Joseph Holcomb Adams

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Joseph Holcomb Adams joins to discuss the important topic of guruism and cult dynamics in psychedelic communities. Joseph is an ethicist who specializes in issues related to psychedelics, altered states, and transformative experiences. In this conversation, Joseph introduces the concepts of a guru, guruism, and cult dynamics. He describes the social-psychological mechanisms behind the devotee-guru relationship and the development of ideological conformity in cults, explaining how the heightened states induced by psychedelics can contribute to these dynamics if participants and...

info_outline
Encore episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) show art Encore episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c)

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode of the Psychedelic Medicine Podcast, Adam Aronovich, PhD(c) returns to discuss issues of psychedelic self-absorption—and how to avoid these traps. According to Adam, he is a PhD candidate in medical anthropology, the creator and curator of Healing from Healing, a trophy husband and dad. In this conversation, Adam revisits his previous discussion of psychedelic narcissism and explains why he’s now somewhat more critical of the term. However, Adam still sees issues around cultivating epistemic humility and acknowledging the political dimensions of healing in psychedelic...

info_outline
Psilocybin for Obsessive-Compulsive Disorder (OCD) with Sorcha O'Connor, PhD(c) show art Psilocybin for Obsessive-Compulsive Disorder (OCD) with Sorcha O'Connor, PhD(c)

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Sorcha O'Connor, PhD(c) joins to discuss the research into the use of psilocybin to address obsessive-compulsive disorder (OCD). Sorcha is completing her neuroscience PhD at Imperial College London, specialising in mental health research. She led PsilOCD, a pioneering study investigating low-dose psilocybin as a treatment for both the clinical symptoms and cognitive features of OCD. In this conversation, Sorcha introduces obsessive-compulsive disorder and discusses the ways medical professionals are currently thinking about this and other related conditions. She mentions that...

info_outline
Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND show art Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Erica Zelfand, ND joins to discuss the important topic of pill shaming in psychedelic communities and how psychedelic medicine and traditional pharmaceuticals can both support healing. Dr. Erica Zelfand specializes in integrative mental health, bridging the gaps between conventional and alternative medicine. In addition to seeing patients in private practice, she also teaches facilitation internationally and leads retreats through Right to Heal. In this conversation, Dr. Zelfand tackles the issue of pill shaming in psychedelic communities, showing why this rhetoric falls short...

info_outline
Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA, LPC show art Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA, LPC

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode of the Psychedelic Medicine Podcast, Keith Kurlander, MA, LPC, joins to discuss the important topic of integration practices for challenging psychedelic experiences. Keith is the Co-Founder of the Integrative Psychiatry Institute, the largest professional education company specializing in integrative mental health and psychedelic therapy. In this conversation, Keith begins by exploring the different types of challenging psychedelic experiences and various lingering effects one may experience following a difficult psychedelic journey. He discusses these from a trauma-informed...

info_outline
 
More Episodes

In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca.

In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine. 

 

In this episode you'll hear:

  • The history of ketamine
  • The pharmacology of ketamine’s dissociative effect
  • The relationship between ketamine dose and antidepressant effect 
  • The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials
  • How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments

 

Quotes:

“We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58]

“Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19]

 

Links:

Dr. Eriksson on LinkedIn

HMNC Brain Health on LinkedIn

HMNC Brain Health website

Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD

Psychedelic Medicine Association

Porangui